Business
-
Novartis Pharmaceuticals Canada has announced the launch of the Ultibro Breezhaler indacaterol/glycopyrronium bromide DPI for the treatment of COPD in Quebec, the first province in Canada to reimburse the inhaler. The Régie de l’assurance maladie… Read more . . .
-
Vectura Chief Executive Chris Blackwell will step down from that position at the end of June 2015, the company has announced. Blackwell has been with the company since 2002. The company’s board says that it… Read more . . .
-
Afrezza inhaled insulin is now available by prescription in the US, Sanofi and Mannkind Corporation have announced. The FDA approved the insulin DPI for the treatment of type 1 and type 2 diabetes in June… Read more . . .
-
Evoke Pharma has announced that slower than expected enrollment in a Phase 3 clinical trial of its EVK-001 metoclopramide nasal spray for the treatment of diabetic gastroparesis in women will result in delayed completion of… Read more . . .
-
Theravance Biopharma and Mylan announced that they have entered into a development and commercialization agreement for TD-4208, a novel nebulized LAMA for the treatment of COPD and other respiratory diseases that is currently in Phase… Read more . . .
-
Adamis Pharmaceuticals has announced that the US and Japanese patent offices have approved applications for patents related to the Taper dry powder inhaler, an API-only device that was developed initially by 3M Drug Delivery Systems.… Read more . . .
-
GlaxoSmithKline has announced that both the Arnuity Ellipta fluticasone furoate DPI and the Incruse Ellipta umeclidinium bromide DPI are now available in the US. Arnuity Ellipta was approved by the FDA in August 2014 for… Read more . . .
-
Boehringer Ingelheim has announced that the Spiriva Respimat tiotropium soft mist inhaler is now available in the United States. Patients will also still be able to purchase Spiriva Handihaler, the company said. The FDA approved… Read more . . .
-
NovaBiotics, which has plans to develop an inhaled version of its Lynovex cysteamine (NM001) for the treatment of cystic fibrosis, has announced that it has raised £5 million in a private placement from Woodford Investment… Read more . . .
-
Aradigm Corporation announced that it has received patents for its Pulmaquin inhaled ciprofloxacin from the European and Australian patent offices. The European patent (EU Patent No. 2,079,443) is titled “Dual Action, Inhaled Formulations Providing Both… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden